This article is more than 5 years old. Information may no longer be current.

Novaliq, AFT Pharmaceuticals enter licensing agreement for NovaTears

Issue: March 2017

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Novaliq and AFT Pharmaceuticals have entered a strategic licensing agreement for the commercialization of Novaliq’s NovaTears in Australia and New Zealand, Novaliq announced in a press release.

AFT will have an exclusive license to commercialize NovaTears, used to treat evaporative dry eye diseases, in Australia and New Zealand, and Novaliq will receive an undisclosed upfront payment and royalties on the product’s net sales, under the terms of the agreement.

“NovaTears provides a highly differentiated and clinically validated treatment option that significantly improves the signs and symptoms of evaporative DED and meibomian gland dysfunction,” Christian Roesky, PhD, CEO of Novaliq, said in the release.